CSF Biomarkers as evidence for Alzheimers Dementia

Lieferzeit: Lieferbar innerhalb 14 Tagen

39,90 

Towards early diagnosis of the most prevalent Neurodegenerative disorder

ISBN: 6200503400
ISBN 13: 9786200503404
Autor: Huded, Chandrashekar
Verlag: LAP LAMBERT Academic Publishing
Umfang: 80 S.
Erscheinungsdatum: 22.01.2020
Auflage: 1/2020
Format: 0.5 x 22 x 15
Gewicht: 137 g
Produktform: Kartoniert
Einband: KT
Artikelnummer: 8553850 Kategorie:

Beschreibung

With the worlds population ageing there is an increase in the prevalence of dementia which is a disease of aging population. It is one of the major causes of disability and dependency among older people worldwide. Alzheimers disease is the most frequent cause of dementia accounting for almost half of the cases of dementia. The diagnostic criteria for Alzheimers Dementia(AD) is mainly clinical with no definitive investigations to confirm the diagnosis. There is no curative treatment for this dreaded disease at this juncture. But over the years significant advances in our understanding of pathophysiological process of AD has occurred. With growth in the scientific knowledge efforts are being made to find reliable biomarkers for early diagnosis of Alzheimers Dementia. Various biomarkers have been studied including structural MRI, molecular neuroimaging with PET and cerebrospinal fluid analyses and blood analyses. This book gives a review of various biomarkers studied till now as evidence for Alzheimers disease and later describes a study where CSF biomarkers (Abeta 42 and p-tau 181) were used as evidence for Alzheimers Dementia.

Autorenporträt

Dr Chandrashekar. B. Huded, has completed his MBBS from the RGUHS, Bangalore and went on to pursue his residency in Psychiatry from the prestigious National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore.He is currently working as Asst. Prof. of Psychiatry at Gulbarga Institute of Medical Sciences, India.

Das könnte Ihnen auch gefallen …